TY  - JOUR
T1  - Dietary Supplementation with Calcium in Artemisinin-Based Combination Drug 
  Administered Rat and Risk of Cardiovascular Disease
AU - O. Ajani, Emmanuel AU - A. Salau, Bamidele AU - A. Bamisaye, Fisayo AU - E. Olooto, Wasiu 
JO  - Agricultural Journal
VL  - 8
IS  - 2
SP  - 89
EP  - 93
PY  - 2013
DA  - 2001/08/19
SN  - 1816-9155
DO  - aj.2013.89.93
UR  - https://makhillpublications.co/view-article.php?doi=aj.2013.89.93
KW  - Lipid profile
KW  -cardiovascular disease
KW  -calcium
KW  -ACT
KW  -malaria
KW  -rat
KW  -Nigeria
AB  - Reports on the role of calcium on predisposition to cardiovascular disease have been rather inconsistent while studies on its interaction with other medications are ongoing. Researchers therefore, investigated the effect of separate and combine administration of calcium supplement with artemisinin-based combination drug on hepatic and serum lipid profile. A total of 32 male wistar rats were randomly assigned into 4 groups of 8 rats each. The control (Group A) received water. Group B and D were placed on 10 mg kg<SUP>-1</SUP> calcium twice daily for 4 weeks. On the 30th day, therapeutic dose of artemisinin-based combination was simultaneously administered to group C and D twice daily for 3 days. All the rats were then sacrificed after 12 h fasting, blood was withdrawn and the liver removed and homogenized in an appropriate buffer. Biochemical analysis showed no significant (p&gt;0.05) variation in hepatic triaacylglycerol in all the treated groups whereas calcium supplementation was observed to induce a significant (p&lt;0.05) reduction in hepatic cholesterol. Significant elevations due to calcium supplementation were also observed in serum total cholesterol, LDL cholesterol level and atherogenic risk index with a concomitant reduction in serum HDL cholesterol. No significant change was observed in serum total cholesterol, triacylglycerol and serum lipoproteins in all other treatment groups. This study suggests that calcium supplementation may predispose to cardiovascular disease and that its co administration with ACT may not aggravate nor reduced the predisposition risk.
ER  -